M
Mekanistic Therapeutics
Dual EGFR and PI3K precision oncology inhibitors
About Mekanistic Therapeutics
Mekanistic Therapeutics is a precision oncology company developing single-molecule kinase inhibitors designed to hit multiple cancer pathways at once and reduce resistance and combination-therapy complexity. Its lead candidate MTX-531 is a first-in-class dual EGFR and PI3K inhibitor intended to deliver coordinated pathway blockade with a simpler dosing profile than two-drug regimens.
The company is a University of Michigan spin-out led by kinase and computational chemistry experts, advancing MTX-531 through IND-enabling work and clinical preparation for resistant solid tumors such as head and neck cancers, with broader oncology potential. Preclinical results and NCI partnership support the dual-inhibition approach, including efforts to limit hyperglycemia toxicity seen with some PI3K agents.
Business model is biotech drug discovery and development for targeted cancer therapy. Official website mekanistic.com and LinkedIn mekanistic-therapeutics brand Mekanistic Therapeutics for dual EGFR/PI3K oncology assets.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jun 2022 | $30M | $120M | Undisclosed | ↗ |
| SPINOUT✓Other financing | Jan 2022 | $0 | — | University of Michigan | — |
Growth signals
Latest recorded traffic for Mekanistic Therapeutics is 630 monthly website visits, up 6200% over the last three months. Mekanistic Therapeutics's team grew 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Mekanistic Therapeutics in the Minneapolis ecosystem
The Mekanistic Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
University of Michigan
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mekanistic Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mekanistic Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










